← Back to headlines
Boehringer-Zealand Drug Shows Significant Weight Loss in Late-Stage Trial
A drug developed by Boehringer Ingelheim and Zealand Pharma demonstrated an average of 16.6% weight loss in patients during a late-stage clinical trial, indicating potential for obesity treatment.
28 Apr, 13:21 — 28 Apr, 13:21
Sources
Showing 1 of 1 sources
